122 results about "Sublingual Tablet" patented technology

The present invention relates to a sublingual tablet and to the method for the preparation thereof.

This disclosure provides compositions of vitamin B₁₂, and methods of treatment or amelioration of a disease associated with vitamin B₁₂ deficiency. The composition can take the form of a solid, semi-solid, gummy, or chewable lozenge. The composition can also take the form of a troche, a candy, a wafer, an orally disintegrating tablet, a sublingual tablet, a buccal tablet, a buccal patch, an oral dissolvable film, an aerosol or spray, a lip balm, and chewing gum.

The invention discloses a sildenafil citrate sublingual tablet and a preparation method thereof. The sildenafil citrate sublingual tablet is prepared from 1 part by weight of sildenafil citrate and 4 to 8 parts by weight of pharmaceutical adjuvant , wherein the pharmaceutical adjuvant comprises 2 to 4 percent of disintegrant, 94 to 96 percent of diluter, 0.5 to 1.2 percent of lubricator, 0.3 to 1 percent of corrective and 0.1 to 0.2 percent of binder, which are based on the total weight of the pharmaceutical adjuvant. Test results show that the prepared sublingual tablet has shorter disintegration time, higher dissolving speed in vitro and higher body bioavailability than the conventional tablets.

The invention provides a butylphthalide sublingual preparation. The butylphthalid sublingual preparation contains butylphthalide, lauric acid polyethylene glycol glyceride, an excipient, an adsorbent and a lubricating agent. A butylphthalide solid dispersion prepared by taking lauric acid polyethylene glycol glyceride as a carrier can be quickly dissolved in vitro, and a sample is prepared by adopting a hot melting extrusion method, so that drug loading capacity is high and sample stability is good.

The invention discloses a respiratory syncytial virosome vaccine, which mainly comprises a respiratory syncytial virosome, wherein the virosome comprises a complete respiratory syncytial virus (RSV) surface, and can stimulate good dual cell and body fluid immune response. The virosome protein antigens are prepared into formulations such as injection, nasal spray, sublingual tablet and transdermal agent by adding or not adding an adjuvant, can safely and effectively prevent RSV infection after being immunologically inoculated to different animals or people, and provide the ideal vaccine for the safe and effective immune prevention and control of the RSV infection of different age groups. Researches show that the respiratory syncytial virosome vaccine has a good immunological protection effect on the different age groups.

The invention provides a zolmitriptan sublingual tablet, which is characterized in that it contains the main drug zolmitriptan, a disintegrating agent and a filler. In every 1000 sublingual tablets, the content of zolmitriptan is 1 -50g, the content of disintegrating agent is 2-20g, the content of filler is 40-200g; it also contains 0-20g of corrective agent, 10-60g of binder and 0.5-5g of lubricant. The present invention utilizes the characteristics of non-keratinized sublingual mucosa, rich capillaries, and fast blood flow, aiming at the absorption of zolmitriptan ordinary tablets through the gastrointestinal tract, slow onset of action, first-pass effect, and low bioavailability. The deficiencies of advanced prior art, zolmitriptan is made into sublingual tablet, can make it absorb through sublingual mucosa, directly enter blood circulation through jugular vein and superior vena cava, take effect rapidly; Avoid oral administration The first-pass effect improves bioavailability and ensures curative effect. Moreover, water is not needed when taking the medicine, and it is placed under the tongue to contain it, so it is convenient to take and has a good taste. With the characteristics of rapid onset of action, convenient administration and high bioavailability, it can provide patients with a new treatment option and fill the gap in the market.

The invention discloses an acidum citricum hypoglossal tablet and the preparing method, relating to a tablet and the preparation method. The invention means to solve problems: current acidum citricum are all oral tablets and capsule, the content is large and increases liver injury, and it is easy to generate adverse effect. The comprised component and their weight proportion are as follows: acidum citricum 20 -30 units, manna sugar 45-65 units, lactin 65-105 units, sweetener 0. 5-1. 5 units, ethanol solution with concentration being 5%PVPK30 30 -40 units and dolomol 4-8 units. The preparation method comprises following steps: sifting sot material with nylon screen of 18-20 order to produce particular, drying at 55-65 Deg. C; sifting granular with screen of 14-16 order and placing for 5-7 hours for sheeting. The tablet is characterized by small content, increased biological utilization rate, low adverse effect rate, and the method is characterized by short and simple process.

The invention relates to a composition which contains asenapine maleate and is taken by sublingual or buccal administration and a preparation method of the compositionBy using the asenapine maleate as an active ingredient and using an easy-sublimating pore-foaming agent, sublingual tablets which are quickly dispersed and dissolved under the tongue in tens of seconds are prepared, thus the active ingredient can be absorbed quickly through sublingual veins so as to enter blood circulation directly. The composition takes effect quickly and is convenient to take. The invention also discloses a novel in vitro evaluation method.

A buprenorphine hydrochloride/naloxone hydrochloride sublingual tablets with low misuse potential , said tablets contain medicinal contents of buprenorphine hydrochloride and naloxone hydrochloride, part by weight thereof is 2:1-6:1, 1) using alcohol to dissolve regulator corrigent and bond of PH of prescription amount for use; 2) grinding main medicine buprenorphine hydrochloride/naloxone hydrochloride, filler and lubricant and sifting out thereof; 3) mixing evenly the prescription amount of buprenorphine hydrochloride/naloxone hydrochloride, filler, bond and disintegrating agent, thereafter adding contents in step 1 to prepare into soft stuff, again making into pellet, drying, sorting out, adding lubricant again, mixing evenly and pressing into tablet.

The invention belongs to the field of pharmaceutical preparations, and relates to ramelteon sublingual tablets and a preparation method thereof. The sublingual tablet contains effective amounts of ramelteon, a filler, a disintegrant, a lubricant, and a flavoring agent, and the proportion of a main drug is 0.1 to 0.5%; the filler is selected from one or a combination of mannitol, lactose, sucrose and xylitol; the disintegrant is selected from one or the combination of crospovidone, cross linked sodium carboxymethyl cellulose, and low-substituted hydroxypropyl cellulose; and the lubricant is selected from one or a combination of magnesium stearate, aerosil, and sodium stearyl fumarate; and the flavoring agent is mint flavor. The invention also provides the preparation method of the ramelteonsublingual tablets, that is, ramelteon and the filler are ground and mixed by a ball mill, and mixed with the disintegrating agent, the lubricant, and the flavoring agent, and the materials are pressed to prepare tablets. The ramelteon sublingual tablet of the invention can avoid the first pass effect of the liver and improve the bioavailability.

The invention discloses a ginkgolide sublingual tablet, belonging to the technical field of a pharmaceutical composition, and a preparation method thereof. The sublingual tablet comprises the following materials in parts by weight: 1-200 parts of ginkgolide, 2-20 parts of a disintegrating agent and 40-200 parts of a filler, wherein the ginkgolide includes the following components in percentage by weight: 35-50% of ginkgolide A, 6-16% of ginkgolide B, 15-25% of ginkgolide C and 30-45% of bilobalide. The ginkgolide sublingual tablet disclosed by the invention is prepared by organically combining the disintegrating agent, the filler and the like; the sublingual tablet, which is located under the tongue when being taken, can disintegrate rapidly under the tongue; the sublingual tablet is absorbed through sublingual mucosa and directly participates in blood circulation through jugular vein and superior vena cava to become effective rapidly, so as to relieve migraine rapidly.

The invention relates to a preparation method for a rapid-disintegrating directly-pressed granular mannitol preparation. The preparation method comprises the following steps of: 1) weighing the following raw materials in percent by weight according to a particle mannitol formula: 0.2-5.0 percent of adhesive and 8-2 percent of purified water, pouring the adhesive into the purified water and preparing adhesive slurry for future use; 2) putting crushed or uncrushed mannitol and 0.2-5.0 percent of disintegrating agent in a high-speed agitating and granulating machine, starting up the high-speed agitating and granulating machine, adding the slurry and preparing high-quality soft materials; 3) transferring the product wet granules into a fluidized drying machine for drying, screening the dried materials and completely tidying the granules; and 4) mixing the screened and tidied materials with lubricating agent, pressing the mixture into tablets and conducting hardness and disintegration tests. By adopting the preparation method, widely applicable directly-pressed granules with different content and fineness can be produced, have a rapid disintegrating characteristic and satisfy the American standard that the disintegrating time of sublingual tablets is less than or equal to 30 seconds. Moreover, the preparation method has the advantages of easiness in operation, low production cost, simple technology and high product quality.

The invention relates to medicine, and specifically to synthetic biologically active derivatives of carbopentoxysulfanilic acid. The novel substance comprises a (2,6-dichlorophenyl)amide salt of carbopentoxysulfanilic acid of general formula:

The present invention relates to an abiraterone acetate sublingual tablet, wherein the preparation method comprises: dissolving abiraterone acetate, hydroxypropylcellulose and povidone in an organic solvent, adding a filler, uniformly dispersing, filling, carrying out freeze-drying, and packaging to form the abiraterone acetate sublingual tablet. Compared to the abiraterone acetate sublingual tablet in the prior art, the abiraterone acetate sublingual tablet of the present invention has the following advantages that the abiraterone acetate sublingual tablet can be subjected to complete dissolution within 10 min so as to ensure the efficacy of the medicine, the complex micro-powder treatment does not required, and the bioavailability of the medicine is substantially improved.

The invention provides a freeze-dried sublingual tablet containing hydrophobic active substances, which is prepared from active substances and auxiliary materials and is characterized in that the auxiliary materials include medicine carriers and assistants, wherein the medicine carriers are natural polysaccharide high molecular materials which exist in water in nano sizes and have hydrophobic regions, and the active substances are hydrophobic active substances. The freeze-dried sublingual tablet containing hydrophobic active substances, provided by the invention, can effectively and quickly carry and supplement hydrophobic medicines, and the medicines can be carried uniformly, thereby being favorable for playing roles of the medicines; and meanwhile, the hydrophobic medicines are prepared into the freeze-dried sublingual tablets, and then the medicines can quickly pass through the sublingual region to enter the blood for circulation, thereby playing roles.

A method and composition for the treatment of infertility is disclosed. The method relates to using progesterone dilutions, or any other steroid hormone, to treat infertility. The hormone dilution may be administered sublingually, by drops or sublingual tablet or, an intradermal route of administration may be chosen.